Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Vaccine

• Publication date

  2004-04-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.VACCINE.2004.01.031PMID 15068840
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-γ1

  2003cited by this paper
• Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

  2003cited by this paper
• Overcoming Immunity to a Viral Vaccine by DNA Priming before Vector Boosting

  2003cited by this paper
• T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev

  2002cited by this paper
• Protection of Rhesus Macaques against Lethal Plasmodium knowlesi Malaria by a Heterologous DNA Priming and Poxvirus Boosting Immunization Regimen

  2002cited by this paper
• Safety, Tolerability, and Lack of Antibody Responses After Administration of a PfCSP DNA Malaria Vaccine via Needle or Needle-Free Jet Injection, and Comparison of Intramuscular and Combination Intramuscular/Intradermal Routes

  2002cited by this paper
• Progress and challenges for malaria vaccines

  2002cited by this paper
• Induction of CD4+ T cell-dependent CD8+ type 1 responses in humans by a malaria DNA vaccine

  2001cited by this paper
• Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.

  2001cited by this paper
• Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen.

  2001cited by this paper
• Two-step chromatographic purification of recombinant Plasmodium falciparum circumsporozoite protein from Escherichia coli.

  2001cited by this paper
• Gene Combination Raises Broad Human Immunodeficiency Virus-Specific Cytotoxicity

  2001cited by this paper
• A non-sense mutation and protection from severe malaria

  2001cited by this paper
• Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

  2001cited by this paper
• Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines.

  2000cited by this paper
• The Complexity of Protective Immunity Against Liver-Stage Malaria1 2

  2000cited by this paper
• Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine.

  2000cited by this paper
• Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers.

  2000cited by this paper
• Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

  1999cited by this paper
• Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

  1999cited by this paper
• In vitro expression and in vivo immunogenicity of Plasmodium falciparum pre-erythrocytic stage DNA vaccines.

  1998cited by this paper
• Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

  1998cited by this paper
• Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.

  1998cited by this paper
• An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi.

  1997cited by this paper
• A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.

  1997cited by this paper
• Malaria vaccine development: a multi-immune response approach

  1996cited by this paper
• Cancer Gene Therapy Using Plasmid DNA: Purification of DNA for Human Clinical Trials

  1995cited by this paper
• Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

  1995cited by this paper
• Deaths during mountaineering at extreme altitude.

  1988cited by this paper
• Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine.

  1987cited by this paper
• Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli.

  1987cited by this paper
• SECTION OF ZOOLOGY.

  1895cited by this paper

• Malaria Vaccines: Progress to Date

  2023cites this paper
• Sporozoite immunization: innovative translational science to support the fight against malaria

  2023cites this paper
• Cryopreserved Sporozoites with and without the Glycolipid Adjuvant 7DW8-5 Protect in Prime-and-Trap Malaria Vaccination.

  2022cites this paper
• Minicircles for a two-step blood biomarker and PET imaging early cancer detection strategy.

  2021cites this paper
• DNA Vaccines: A Promising Vaccine for the Future

  2021cites this paper
• Optimizing RTS,S vaccination strategies: give it your best parting shot.

  2020cites this paper
• Construction of a novel tetravalent dengue vaccine with a Salmonella Typhimurium bacterial ghost and evaluation of its immunogenicity and protective efficacy using a murine model.

  2019cites this paper
• Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection

  2017cites this paper
• Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease

  2016cites this paper
• Recent Advances in Chitosan-Based Gene Carrier Application and Design

  2016cites this paper
• Decrease in circulating CD25(hi)Foxp3(+) regulatory T cells following vaccination with the candidate malaria vaccine RTS,S.

  2016cites this paper
• Development of oral DNA vaccine based on chitosan nanoparticles for the immunization against reddish body iridovirus in turbots (Scophthalmus maximus)

  2016cites this paper
• Plasmodium knowlesi: a relevant, versatile experimental malaria model

  2016cites this paper
• The march toward malaria vaccines.

  2015cites this paper
• The March Toward Malaria Vaccines.

  2015cites this paper
• Genetic Vaccines and Therapy

  2015cites this paper
• Using Plasmids as DNA Vaccines for Infectious Diseases

  2014cites this paper
• Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.

  2014cites this paper
• Molecular delivery of plasmids for genetic vaccination.

  2013cites this paper
• Aptamer–Nanomaterial Conjugates for Medical Applications

  2013cites this paper
• Prime boost regimens for enhancing immunity: magnitude, quality of mucosal and systemic gene vaccines

  2012cites this paper
• A review of malaria vaccine clinical projects based on the WHO rainbow table

  2012cites this paper
• Plasmodium falciparum malaria vaccines: current status, pitfalls and future directions

  2012cites this paper
• Malaria vaccines: looking back and lessons learnt.

  2011cites this paper
• The RTS,S vaccine candidate for malaria

  2011cites this paper
• Effect of nanoparticle coating on the immunogenicity of plasmid DNA vaccine encoding P. yoelii MSP-1 C-terminal.

  2011cites this paper
• Prime-boost immunisation against tropical theileriosis with two parasite surface antigens: evidence for protection and antigen synergy.

  2011cites this paper
• Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration.

  2011cites this paper
• A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations.

  2011cites this paper
• Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component

  2011cites this paper
• Immune responses elicited by co‐immunization of Plasmodium vivax and P. falciparum MSP‐1 using prime‐boost immunization strategies

  2011cites this paper
• Molecular studies on plasmodium during development in the mosquito

  2011cites this paper
• DNA vaccines: a rational design against parasitic diseases

  2010cites this paper
• Low Concentrations of Anti-Aβ Antibodies Generated in Tg2576 Mice by DNA Epitope Vaccine Fused with 3C3d Molecular Adjuvant Do Not Affect AD Pathology

  2010cites this paper
• Safety of the Malaria Vaccine Candidate, RTS,S/AS01E in 5 to 17 Month Old Kenyan and Tanzanian Children

  2010cites this paper
• PATH Malaria Vaccine Initiative (MVI): Perspectives on the status of malaria vaccine development

  2010cites this paper
• Molecular vaccines for malaria

  2010cites this paper
• Chapter 65 – Malaria

  2009cites this paper
• Immunosurveillance and immunoediting--can the immune response be made more "immunodemocratic"?

  2009cites this paper
• Genetic heterologous prime–boost vaccination strategies for improved systemic and mucosal immunity

  2009cites this paper
• DNA Vaccines for Biodefense and Emerging and Neglected Infectious Diseases

  2009cites this paper
• Plasmodium falciparum apical membrane antigen 1 vaccine elicits multifunctional CD4 cytokine-producing and memory T cells.

  2009cites this paper
• Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children

  2009cites this paper
• Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.

  2009cites this paper
• Salmonella enterica serovar Typhi live vector vaccines finally come of age

  2009cites this paper
• Plasmodium falciparum malaria vaccines in development

  2008cites this paper
• Gene Disruption of Plasmodium falciparum p52 Results in Attenuation of Malaria Liver Stage Development in Cultured Primary Human Hepatocytes

  2008cites this paper
• Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses.

  2008cites this paper
• Current progress of DNA vaccine studies in humans

  2008cites this paper
• Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques.

  2007cites this paper
• Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity to Plasmodium falciparum CS Compared to That with Either Malaria Vaccine Alone

  2007cites this paper
• Protection of Rhesus Monkeys by a DNA Prime/Poxvirus Boost Malaria Vaccine Depends on Optimal DNA Priming and Inclusion of Blood Stage Antigens

  2007cites this paper
• Effect of Plasmid DNA Vaccine Design and In Vivo Electroporation on the Resulting Vaccine-Specific Immune Responses in Rhesus Macaques

  2007cites this paper
• Production of clinical-grade plasmid DNA for human Phase I clinical trials and large animal clinical studies.

  2007cites this paper
• Development of safer pertussis DNA vaccine expressing non-toxic C180 polypeptide of pertussis toxin S1 subunit.

  2007cites this paper
• Two decades of commitment to malaria vaccine development: GlaxoSmithKline Biologicals.

  2007cites this paper
• Malaria vaccines: are we getting closer?

  2007cites this paper
• GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

  2007cites this paper
• Early Gamma Interferon and Interleukin-2 Responses to Vaccination Predict the Late Resting Memory in Malaria-Naïve and Malaria-Exposed Individuals

  2006cites this paper
• Advances in vaccine development against the pre-erythrocytic stage of Plasmodium falciparum malaria

  2006cites this paper
• Genetic vaccination approaches against malaria based on the circumsporozoite protein

  2006cites this paper
• Immune responses against PSMA after gene-based vaccination for immunotherapy – A: results from immunizations in animals

  2006cites this paper
• Human Metapneumovirus Fusion Protein Vaccines That Are Immunogenic and Protective in Cotton Rats

  2006cites this paper
• Long‐term persistence of hepatitis B surface antigenand antibody induced by DNA‐mediated immunization results in liver and kidney lesions in mice

  2006cites this paper
• Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.

  2006cites this paper
• Vaccines for preventing malaria (pre-erythrocytic).

  2006cites this paper
• A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite Challenge

  2006cites this paper
• Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene Inserts

  2006cites this paper
• Heterologous Prime-Boost Immunisation Regimens Against Infectious Diseases

  2006cites this paper
• Preclinical and Clinical Safety Studies on DNA Vaccines

  2006cites this paper
• Human clinical trials of plasmid DNA vaccines.

  2005cites this paper
• Naked DNA Immunization for Prevention of Prostate Cancer in a Dunning Rat Prostate Tumor Model

  2005cites this paper
• Toxicity of cationic lipid-DNA complexes.

  2005cites this paper
• Enhanced Breadth of CD4 T-Cell Immunity by DNA Prime and Adenovirus Boost Immunization to Human Immunodeficiency Virus Env and Gag Immunogens

  2005cites this paper
• Plasmid vaccines and therapeutics: from design to applications.

  2005cites this paper
• DNA Vaccine

  2005cites this paper
• Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41.

  2005cites this paper
• Boosting of DNA Vaccine-Elicited Gamma Interferon Responses in Humans by Exposure to Malaria Parasites

  2005cites this paper
• Immunogene Therapy with Nonviral Vectors

  2005cites this paper
• Toxicity of Cationic Lipid-DNA Complexes.

  2005cites this paper
• DNA vaccines against tropical parasitic diseases

  2005cites this paper
• Phase I Malaria Vaccine Trial with a Long Synthetic Peptide Derived from the Merozoite Surface Protein 3 Antigen

  2005cites this paper
• Gene medicines: the end of the beginning?

  2005cites this paper
• Building better T‐cell‐inducing malaria vaccines

  2005cites this paper
• Recombinant Protein Immunization with Malaria DNA and Cell and Antibody Responses by Sequential T + and CD4 + Induction in Humans of CD8

  2004cites this paper
• DNA vaccines: designing strategies against parasitic infections

  2004cites this paper
• Induction in Humans of CD8+ and CD4+ T Cell and Antibody Responses by Sequential Immunization with Malaria DNA and Recombinant Protein1

  2004cites this paper
• Antimicrobial agents: bacterial/ fungal Impactof real-timefungalsusceptibilityon clinical practices Related review: Impact of real-time fungal susceptibility on clinical practices (pp 511–515)

  2004cites this paper
• Reducing the immunostimulatory activity of CpG-containing plasmid DNA vectors for non-viral gene therapy

  2004cites this paper
• Characterisation of heterologous prime-boost vaccination strategies : an investigation into the nature and delivery of vaccines and the subsequent generation of immune responses.

  2004cites this paper
• Recent advances in research and control of malaria, leishmaniasis, trypanosomiasis and schistosomiasis.

  2003cites this paper